Short-Acting Insulin Market: Trends, Innovations, and Growth Outlook
The Global Market For Short-Acting Insulin will reach USD 10287.9 Million by 2030, expanding at a CAGR of 1.18% from USD 9257.1 Million in 2021. The market for rapid-acting insulin is dominated by three companies: Sanofi, Novo Nordisk, and Eli Lilly. Each of these companies has built its brand name in the marketplace.